SCHEMBL5656179

SCHEMBL5656179

Oc1ccc2c(ccc3cncnc32)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.50
MEN1 O00255 2/20 0.50
KMT2A Q03164 2/20 0.50
POLB P06746 1/20 0.50
CYP11B1 P15538 2/20 0.41
CYP11B2 P19099 2/20 0.41
CYP3A4 P08684 2/20 0.41
CYP17A1 P05093 1/20 0.41
HSD17B1 P14061 1/20 0.39
CSNK2A2 P19784 1/20 0.38
CSNK2B P67870 1/20 0.38
EGFR P00533 2/20 0.37
CYP19A1 P11511 1/20 0.37
CYP1A2 P05177 1/20 0.36
PDGFRB P09619 1/20 0.36
PDGFRA P16234 1/20 0.36
PIK3CG P48736 1/20 0.36
ESR2 Q92731 2/20 0.35
FTO Q9C0B1 1/20 0.35
ERN1 O75460 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22966311 0.79 CSNK2A2 (0.39) LMNAKMT2APOLBCSNK2A2CSNK2B
SCHEMBL25850566 0.73 EGFR (0.48) LMNACYP3A4EGFRALOX15TSHR
SCHEMBL1056993 0.73 EGFR (0.52) LMNAMEN1KMT2APOLBCYP3A4
SCHEMBL277541 0.73 EGFR (0.60) MEN1KMT2ACYP11B1CYP11B2CYP3A4
SCHEMBL17917476 0.73 IMPDH2 (0.44) LMNACYP3A4EGFRCYP1A2ERN1
SCHEMBL276645 0.73 EGFR (0.60) HSD17B1EGFRPDGFRBPDGFRAPIK3CG
SCHEMBL10837840 0.73 MEN1 (0.56) LMNAMEN1KMT2APOLBCYP3A4
SCHEMBL31126641 0.73 MEN1 (0.56) LMNAMEN1KMT2APOLBCYP3A4
SCHEMBL30441984 0.73 HPRT1 (0.52) LMNACYP3A4EGFRCYP1A2TSHR
SCHEMBL19350430 0.73 HPRT1 (0.52) LMNACYP3A4EGFRCYP1A2TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7166593-B2 Glucocorticoid receptor modulators PFIZER, INC. (US) 2007-01-23 US disclosed
US-20040176595-A1 Glucocorticoid receptor modulators PFIZER, INC. 2004-09-09 US disclosed
US-6699893-B2 DIETETICS; ANTIDIABETIC AGENTS; ANTIINFLAMMATROY AGENTS PFIZER INC 2004-03-02 US disclosed
US-20020147336-A1 Glucocorticoid receptor modulators DOW ROBERT L (US) 2002-10-10 US disclosed
US-6380223-B1 FOR THERAPY OF DISEASES, SUCH AS OBESITY, DIABETES, INFLAMMATION PFIZER INC. 2002-04-30 US disclosed
EP-1175383-A1 GLUCOCORTICOID RECEPTOR MODULATORS Pfizer Products Inc. (US) 2002-01-30 EP disclosed
WO-2000066522-A1 GLUCOCORTICOID RECEPTOR MODULATORS PFIZER PRODUCTS INC. (US) 2000-11-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040176595-A1 Glucocorticoid receptor modulators NR3C1, NR3C2, MC2R LMNA 4718/4885MEN1 4143/4885KMT2A 3825/4885
US-20020147336-A1 Glucocorticoid receptor modulators NR3C1, NR3C2, MC2R LMNA 4723/4885MEN1 4118/4885KMT2A 3884/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.